Skip to content
DataLookout
Menu

INTerpath-014NCT07513376

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 26 versions: 25 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 124 → 129 locations
  2. Minor Study sites: 124 to 126
  3. Minor Trial sites expanded: 117 → 124 locations
  4. Minor Study sites: 117 to 119
  5. Minor Trial sites expanded: 104 → 117 locations
  6. Minor Trial sites expanded: 94 → 104 locations
  7. Minor Study sites: 93 to 94
  8. Notable Eligibility criteria expanded, about 16 words
    • Trial sites expanded: 86 → 93 locations
    • Secondary endpoints: details revised at 6 of 8 entries
  9. Minor Trial sites expanded: 76 → 86 locationsv18
  10. Minor Trial sites expanded: 68 → 76 locationsv17
  11. Minor Trial sites expanded: 60 → 68 locationsv16
  12. Minor Trial sites expanded: 56 → 60 locationsv15
  13. Minor Trial sites expanded: 46 → 56 locationsv13
  14. Minor Trial sites expanded: 42 → 46 locationsv12
  15. Minor Trial sites expanded: 35 → 42 locationsv11
  16. Minor Trial sites expanded: 29 → 35 locationsv10
  17. Minor Trial sites expanded: 17 → 29 locationsv9
  18. Minor Trial sites expanded: 10 → 17 locationsv8
  19. Minor Study sites: 8 to 10v7
  20. Minor Study sites: 7 to 8v6
  21. Minor Study sites: 6 to 7v5
  22. Minor Study sites: 5 to 6v4
  23. Notable Recruitment opened
    • Trial sites expanded: 0 → 3 locations
    v3
  24. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 3
    • Start date changed from estimate of May 11, 2026 to May 4, 2026
    v2
  25. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Disease-Free Survival (DFS) as Assessed by Blinded Independent Central Review (BICR) in Participants With Nonsquamous Non-Small Cell Lung Cancer (NSCLC) in Arm A and Arm C
Timeframe: Up to approximately 98 months

Secondary (8)

DFS as Assessed by BICR
Distant Metastasis-Free Survival (DMFS)
Overall Survival (OS)
Number Participants Who Experience an Adverse Events (AE)
Number of Participants Who Discontinue Study Treatment Due to an AE
Show 3 moreShow less
Change From Baseline in European Organization for Research and Treatment (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Combined Global Health Status / Quality of Life (Items 29 & 30) Scale Combined Score
Change From Baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) Score
Change From Baseline in Role Functioning (EORTC QLQ-C30 Items 6-7) Score

Arms and interventions

Arm A: Intismeran + Pembrolizumab with Berahyaluronidase AlfaExperimental

Participants will receive intismeran 1 mg via intramuscular (IM) injection plus pembrolizumab coformulated with berahyaluronidase alfa 790 mg via subcutaneous (SC) injection.

Arm B: IntismeranExperimental

Participants will receive intismeran 1 mg via IM injection.

Arm C: PlaceboPlacebo comparator

Participants will receive dose-matched placebo via IM injection.

Biologicals: Intismeran, Pembrolizumab coformulated with berahyaluronidase alfa

Other: Placebo

Sites

129 sites in 20 countries

United States 28, Spain 9, Netherlands 8, Turkey (Türkiye) 8, Hungary 7, South Korea 7, Chile 6, Colombia 6, Israel 6, Italy 6, Taiwan 5, Canada 4, Germany 4, Greece 4, Japan 4, Poland 4, United Kingdom 4, Australia 3, Brazil 3, France 3